Vicriviroc malate is a chemical compound that functions primarily as an antiretroviral agent, specifically targeting HIV. It is a small molecule that acts as a CCR5 antagonist, inhibiting the CCR5 co-receptor on the surface of T-cells, which is essential for HIV entry into these cells. This mechanism of action helps to prevent the virus from infecting healthy cells, thereby reducing viral load in patients. Vicriviroc malate is typically administered in a salt form, which enhances its solubility and bioavailability. The compound has undergone various clinical trials to assess its efficacy and safety profile in treating HIV infection. Its chemical structure includes a complex arrangement of carbon, hydrogen, nitrogen, and oxygen atoms, contributing to its pharmacological properties. As with many antiretroviral therapies, potential side effects may include gastrointestinal disturbances, fatigue, and changes in liver enzyme levels, necessitating monitoring during treatment. Overall, vicriviroc malate represents a significant advancement in the ongoing efforts to manage and treat HIV/AIDS.

vicriviroc malate

541503-81-5: 1-((4,6-Dimethyl-5-Pyrimidinyl)Carbonyl)-4-((3S)-4-((1R)-2-Methoxy-1-(4-(Trifluoromethyl)Phenyl)Ethyl)-3-Methyl-1-Piperazinyl)-4-Methylpiperidine Malate

Vicriviroc malate is a CCR5 antagonist with action on blocking HIV entry into cells by targeting the CCR5 receptor and is used for research on HIV treatment.

CAS 541503-81-5: vicriviroc malate

Vicriviroc malate

Ref: 3D-FV104295